Tags

Type your tag names separated by a space and hit enter

Clinical aspects of neuroborreliosis and post-Lyme disease syndrome in adult patients.
Int J Med Microbiol. 2006 May; 296 Suppl 40:11-6.IJ

Abstract

The diagnostic criteria of active neuroborreliosis include inflammatory changes of the cerebrospinal fluid (CSF) and an elevated specific Borrelia CSF-to-serum antibody index, indicating intrathecal Borrelia antibody production. Patients with neuroborreliosis are usually treated with intravenous ceftriaxone for 2-3 weeks. In case of allergy, doxycycline may be used. Treatment efficacy is detected by the improvement of the neurological symptoms and the normalization of the CSF pleocytosis. The measurement of serum and CSF antibodies is not suitable for follow-up, because they frequently persist. Post-Lyme disease (PLD) syndrome is characterized by persistent complaints and symptoms after previous treatment for Lyme borreliosis, e.g., musculoskeletal or radicular pain, dysaesthesia, and neurocognitive symptoms that are often associated with fatigue. There is no formal definition of the PLD syndrome, and its pathogenesis is unclear. Recent controlled studies do not support the use of additional antibiotics in these patients, but recommend primarily symptomatic strategies.

Authors+Show Affiliations

Department of Neurology, Ludwig-Maximilians-University, Klinikum Grosshadern, Marchioninistrasse 15, D-81377 Munich, Germany. hans-walter.pfister@med.uni-muenchen.deNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16524775

Citation

Pfister, Hans-Walter, and Tobias A. Rupprecht. "Clinical Aspects of Neuroborreliosis and post-Lyme Disease Syndrome in Adult Patients." International Journal of Medical Microbiology : IJMM, vol. 296 Suppl 40, 2006, pp. 11-6.
Pfister HW, Rupprecht TA. Clinical aspects of neuroborreliosis and post-Lyme disease syndrome in adult patients. Int J Med Microbiol. 2006;296 Suppl 40:11-6.
Pfister, H. W., & Rupprecht, T. A. (2006). Clinical aspects of neuroborreliosis and post-Lyme disease syndrome in adult patients. International Journal of Medical Microbiology : IJMM, 296 Suppl 40, 11-6.
Pfister HW, Rupprecht TA. Clinical Aspects of Neuroborreliosis and post-Lyme Disease Syndrome in Adult Patients. Int J Med Microbiol. 2006;296 Suppl 40:11-6. PubMed PMID: 16524775.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical aspects of neuroborreliosis and post-Lyme disease syndrome in adult patients. AU - Pfister,Hans-Walter, AU - Rupprecht,Tobias A, Y1 - 2006/03/09/ PY - 2006/3/10/pubmed PY - 2006/9/19/medline PY - 2006/3/10/entrez SP - 11 EP - 6 JF - International journal of medical microbiology : IJMM JO - Int. J. Med. Microbiol. VL - 296 Suppl 40 N2 - The diagnostic criteria of active neuroborreliosis include inflammatory changes of the cerebrospinal fluid (CSF) and an elevated specific Borrelia CSF-to-serum antibody index, indicating intrathecal Borrelia antibody production. Patients with neuroborreliosis are usually treated with intravenous ceftriaxone for 2-3 weeks. In case of allergy, doxycycline may be used. Treatment efficacy is detected by the improvement of the neurological symptoms and the normalization of the CSF pleocytosis. The measurement of serum and CSF antibodies is not suitable for follow-up, because they frequently persist. Post-Lyme disease (PLD) syndrome is characterized by persistent complaints and symptoms after previous treatment for Lyme borreliosis, e.g., musculoskeletal or radicular pain, dysaesthesia, and neurocognitive symptoms that are often associated with fatigue. There is no formal definition of the PLD syndrome, and its pathogenesis is unclear. Recent controlled studies do not support the use of additional antibiotics in these patients, but recommend primarily symptomatic strategies. SN - 1438-4221 UR - https://www.unboundmedicine.com/medline/citation/16524775/Clinical_aspects_of_neuroborreliosis_and_post_Lyme_disease_syndrome_in_adult_patients_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1438-4221(05)00153-0 DB - PRIME DP - Unbound Medicine ER -